plerixafor has been researched along with pomalidomide in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, W; Li, J; Liu, X; Shi, J; Zhang, Z; Zhao, L; Zhou, Y | 1 |
| Hata, H | 1 |
| Adachi, H; Akiyama, M; Doki, N; Fujita, M; Igarashi, A; Inamoto, K; Kaito, S; Kakihana, K; Kishida, Y; Kobayashi, T; Konishi, T; Konuma, R; Kumagai, T; Nagata, A; Najima, Y; Ohashi, K; Sakamaki, H; Toya, T; Wada, A; Yamada, Y; Yoshifuji, K | 1 |
2 review(s) available for plerixafor and pomalidomide
| Article | Year |
|---|---|
A review on the treatment of multiple myeloma with small molecular agents in the past five years.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Combined Modality Therapy; Deubiquitinating Enzymes; Drug Development; Drug Resistance; Histone Deacetylases; Humans; Ikaros Transcription Factor; Immunomodulating Agents; Models, Molecular; Morpholines; Multiple Myeloma; Phthalimides; Piperidones; Proteasome Inhibitors; Treatment Outcome; Ubiquitin-Protein Ligases | 2022 |
[Development of novel agents for multiple myeloma; now and the future].
Topics: Animals; Antibodies, Monoclonal, Humanized; Bendamustine Hydrochloride; Benzoquinones; Benzylamines; Clinical Trials as Topic; Cyclams; Drug Discovery; Drug Therapy, Combination; Heterocyclic Compounds; Humans; Hydroxamic Acids; Lactams, Macrocyclic; Molecular Targeted Therapy; Multiple Myeloma; Nitrogen Mustard Compounds; Oligopeptides; Thalidomide; Vorinostat | 2011 |
1 other study(ies) available for plerixafor and pomalidomide
| Article | Year |
|---|---|
Successful hematopoietic stem-cell mobilization with plerixafor plus granulocyte-colony stimulating factor in multiple myeloma patients treated with pomalidomide.
Topics: Adult; Benzylamines; Cyclams; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Male; Middle Aged; Multiple Myeloma; Thalidomide; Transplantation, Autologous | 2019 |